Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.
You may also be interested in...
AstraZeneca: DECLARE-TIMI Outcomes May Support Competitive Claim For Farxiga In Heart Failure
Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.
US FDA Panel Will Reckon With Need For Diabetes Drug CV Risk Assessments
Cardiovascular and non-CV safety findings from completed outcomes trials to date for eight drugs, as well as the relative paucity of preapproval CV data available for anti-diabetic agents prior to a December 2008 guidance that mandated dedicated risk assessments, may inform advisory committee's view on continuing need for large safety trials.